GSK Plc (GSK)
49.89
-0.98
(-1.93%)
USD |
NYSE |
Sep 04, 16:00
49.93
+0.04
(+0.08%)
Pre-Market: 20:00
GSK Research and Development Expense (Quarterly) : 2.310B for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.310B |
| March 31, 2026 | 2.012B |
| December 31, 2025 | 2.843B |
| September 30, 2025 | 2.124B |
| June 30, 2025 | 2.061B |
| March 31, 2025 | 1.759B |
| December 31, 2024 | 2.353B |
| September 30, 2024 | 1.873B |
| June 30, 2024 | 1.802B |
| March 31, 2024 | 1.741B |
| December 31, 2023 | 1.595B |
| September 30, 2023 | 1.807B |
| June 30, 2023 | 1.646B |
| March 31, 2023 | 1.507B |
| December 31, 2022 | 2.085B |
| September 30, 2022 | 1.526B |
| June 30, 2022 | 1.549B |
| March 31, 2022 | 1.490B |
| December 31, 2021 | 1.850B |
| September 30, 2021 | 1.935B |
| June 30, 2021 | 1.591B |
| March 31, 2021 | 1.539B |
| December 31, 2020 | 1.796B |
| September 30, 2020 | 1.454B |
| June 30, 2020 | 1.618B |
| Date | Value |
|---|---|
| March 31, 2020 | 1.409B |
| December 31, 2019 | 1.544B |
| September 30, 2019 | 1.472B |
| June 30, 2019 | 1.374B |
| March 31, 2019 | 1.291B |
| December 31, 2018 | 1.384B |
| September 30, 2018 | 1.288B |
| June 30, 2018 | 1.258B |
| March 31, 2018 | 1.258B |
| December 31, 2017 | 1.604B |
| September 30, 2017 | 1.370B |
| June 30, 2017 | 1.613B |
| March 31, 2017 | 1.190B |
| December 31, 2016 | 1.227B |
| September 30, 2016 | 1.195B |
| June 30, 2016 | 1.135B |
| March 31, 2016 | 1.098B |
| December 31, 2015 | 1.298B |
| September 30, 2015 | 1.136B |
| June 30, 2015 | 1.143B |
| March 31, 2015 | 1.212B |
| December 31, 2014 | 1.323B |
| September 30, 2014 | 1.257B |
| June 30, 2014 | 1.325B |
| March 31, 2014 | 1.341B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| AstraZeneca PLC | 3.456B |
| Eli Lilly & Co. | 3.819B |
| Merck & Co., Inc. | 9.229B |
| Novartis AG | 2.759B |
| Pfizer Inc. | 2.746B |